General Notices

• NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice
  (NOT-AG-22-001)
  National Institute on Aging
  

• Request for Information (RFI): Inviting comments and suggestions on the development of a healthy aging start-up challenge and bootcamp to foster diversity and accelerate innovation.
  (NOT-AG-21-062)
  National Institute on Aging
  

Notice of Changes to Funding Opportunities

• Notice of Correction to Funding Opportunity Announcement (FOA) PAR-21-065, "Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)"
  (NOT-CA-22-007)
  National Cancer Institute
  

• Notice of Correction in Expiration Date for PAR-22-049, "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)"
  (NOT-CA-22-008)
  National Cancer Institute
  

• Notice of Change to Eligibility of Foreign Components for RFA-CA-21-047, "Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)"
  (NOT-CA-22-009)
  National Cancer Institute
  

• Notice of Change to Award Information for RFA-DK-21-025, "Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)"
  (NOT-DK-22-002)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice to Extend the Expiration Date of PAR-19-158, Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
  (NOT-EB-21-030)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Changes to PAR-20-104, "Biomedical Technology Development and Dissemination Center (RM1 - Clinical Trial Not Allowed)"
  (NOT-GM-22-006)
  National Institute of General Medical Sciences
  

• Notice of Clarification of RFA-MD-21-003, "Resource Center for Tribal Epidemiological Centers (RC-TEC) (U24 Clinical Trial Not Allowed)"
  (NOT-MD-22-002)
  National Institute on Minority Health and Health Disparities
  

• Notice of Participation of OBSSR in PAR-21-277, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)"
  (NOT-OD-22-016)
  Office of Behavioral and Social Sciences Research
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed)
  (NOT-OD-22-011)
  Office of Disease Prevention
  National Institute on Drug Abuse
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional)
  (NOT-OD-22-017)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
  (NOT-CA-22-001)
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  

Funding Opportunities

• Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
  (PAR-22-053)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): November 05, 2024
  
  

• Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
  (PAR-22-054)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): February 23, 2022
  
  

• Limited Competition: Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
  (PAR-22-056)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): September 25, 2022
  
  

• Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed)
  (PAR-22-059)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): February 05, 2022
  
  

• Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)
  (PAR-22-061)
  National Cancer Institute
  Application Receipt Date(s): January 07, 2025
  
  

• Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
  (PAR-22-062)
  National Cancer Institute
  Application Receipt Date(s): January 07, 2025
  
  

• Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)
  (RFA-AG-22-026)
  National Institute on Aging
  Application Receipt Date(s): October 22, 2021
  
  

• RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-078)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): March 17, 2022
  
  

• NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
  (RFA-CA-21-060)
  National Cancer Institute
  Application Receipt Date(s): February 28, 2022
  
  

• NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
  (RFA-CA-21-061)
  National Cancer Institute
  Application Receipt Date(s): February 28, 2022 No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
  (RFA-CA-21-062)
  National Cancer Institute
  Application Receipt Date(s): February 28, 2022
  
  

• Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
  (RFA-CA-22-003)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-22-004)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Renewal - Cooperative Agreement to Support the Joint Institute for Food Safety and Applied Nutrition, JIFSAN (U01) Clinical Trial Not Allowed
  (RFA-FD-22-004)
  Food and Drug Administration
  Application Receipt Date(s): January 07, 2022